Commercial-stage biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) announced on Tuesday that it has received US Food and Drug Administration (FDA) clearance for a clinical trial of its TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for treating moderate-to-severe atopic dermatitis (AD).
ICP-332 demonstrated positive results in a prior China Phase II study, showing better efficacy than other AD treatments. The drug targets the JAK-STAT signalling pathway, crucial in AD development.
At present, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration